Ocular Therapeutix (NASDAQ:OCUL) Announces Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Ocular Therapeutix (NASDAQ:OCUL) posted its earnings results on Monday. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05), Zacks reports. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Ocular Therapeutix Stock Up 2.9 %

Shares of NASDAQ:OCUL opened at $7.14 on Monday. The firm has a market capitalization of $1.12 billion, a PE ratio of -5.41 and a beta of 1.22. Ocular Therapeutix has a 1 year low of $4.06 and a 1 year high of $11.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The firm’s 50-day moving average is $7.89 and its two-hundred day moving average is $8.92.

Insider Activity

In other Ocular Therapeutix news, insider Donald Notman sold 11,119 shares of the stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total transaction of $86,839.39. Following the sale, the insider now directly owns 193,444 shares in the company, valued at $1,510,797.64. This represents a 5.44 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research note on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $17.00.

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.